

Supplementary Information
for
Leveraging heterocycle-fused 1,4-benzoquinone to design chemical modulators
for both metal-free and metal-bound amyloid- β

Yelim Yi,^a Kyungmin Kim,^b Hakwon Kim^{*b} and Mi Hee Lim^{*a}

^aDepartment of Chemistry, Korea Advanced Institute of Science and Technology (KAIST),
Daejeon 34141, Republic of Korea

^bDepartment of Applied Chemistry, Global Center for Pharmaceutical Ingredient Materials, Kyung
Hee University, Gyeonggi-do 1732, Republic of Korea

*To whom correspondence should be addressed: miheelim@kaist.ac.kr and hwkim@khu.ac.kr

Table of Contents

Experimental Section

Materials and Methods	S4
Synthesis of 2a	S5
Synthesis of 1	S7
Preparation of Amyloid- β (A β)	S7
A β Aggregation Experiments	S7
Gel Electrophoresis with Western Blotting (Gel/Western Blot)	S8
Transmission Electron Microscopy (TEM)	S8
Electrospray Ionization–Mass Spectrometry (ESI–MS)	S8
Tandem MS (ESI–MS ²)	S9
Docking Studies	S9
Chemical Transformation of 2a	S9
Synthesis of 2b	S9
Solution Speciation Studies	S11
Metal-binding Studies	S11
Cell Culture	S12
Cell Viability Studies	S12
Fig. S1 ¹ H (400 MHz) and ¹³ C (100 MHz) NMR spectra of 1 in DMSO- <i>d</i> ₆	S14
Fig. S2 ¹ H (400 MHz) and ¹³ C (100 MHz) NMR spectra of 2a in DMSO- <i>d</i> ₆	S15
Fig. S3 ¹ H (400 MHz) and ¹³ C (100 MHz) NMR spectra of 3 in DMSO- <i>d</i> ₆	S16
Fig. S4 ¹ H (400 MHz) and ¹³ C (100 MHz) NMR spectra of 4 in DMSO- <i>d</i> ₆	S17
Fig. S5 ¹ H (400 MHz) and ¹³ C (100 MHz) NMR spectra of 5 in DMSO- <i>d</i> ₆	S18
Fig. S6 Original gel images from Fig. 2, 5, 6, and S13	S19
Fig. S7 Proposed reaction pathways between 2a and A β	S20
Fig. S8 Chemical transformation of 2a monitored by ESI–MS	S21
Fig. S9 Characterization of 2b	S22
Fig. S10 Solution speciation studies of 2b	S23
Fig. S11 Abs spectra of 6 upon treatment of Cu(II)	S24
Fig. S12 Interaction of 2b with Zn(II)–A β ₄₂ investigated by ESI–MS	S25
Fig. S13 Influence of 2a and 2b on preformed A β aggregates generated in the absence and presence of metal ions	S26

Fig. S14	Cu(II)-binding properties of 1 determined by Abs spectroscopy	S27
Fig. S15	Abs spectra of 1 upon treatment of Zn(II)	S28
Fig. S16	Interaction of compounds with A β ₄₂ in the presence of Zn(II) analyzed by ESI-MS	S29
Fig. S17	ESI-MS ² analysis of the singly oxidized A β ₄₂ obtained by incubation with 3	S30
References		S31

Experimental Section

Materials and Methods. All chemical reagents for the syntheses of compounds were purchased from commercial suppliers [Sigma-Aldrich (St. Louis, MO, USA), Tokyo Chemical Industry (Tokyo, Japan), Alfa Aesar (Morecambe, UK), Acros Organics (Brookline, MA, USA), Samchun Chemicals (Seoul, Republic of Korea), and Duksan Chemicals (Incheon, Republic of Korea)] and used without further purification. All glassware was thoroughly dried in a convection oven. Chemical reactions for the syntheses of compounds were monitored using thin-layer chromatography (TLC). The spots were visualized in commercial TLC plates (silica gel 60 F₂₅₄, Merck Co., Rahway, NJ, USA) under ultraviolet (UV) light at 254 nm or 365 nm or by dye such as potassium permanganate solution. Silica gel column chromatography was performed with silica gel 60 (particle size 0.040–0.063 mm, Merck Co.). ¹H and ¹³C nuclear magnetic resonance (NMR) spectra were collected on JNM-ECZ400S (JEOL, Tokyo, Japan; Kyung Hee University, Gyeonggi-do, Republic of Korea) or AVANCE III HD 400 NMR spectrometer (Bruker, Billerica, MA, USA; Department of Chemistry, KAIST, Daejeon, Republic of Korea). Chemical shifts in ¹H NMR spectra were expressed in parts per million (ppm) downfield from tetramethylsilane, and coupling constants were reported in Hertz (Hz). Splitting patterns are indicated: s, singlet; d, doublet; t, triplet; and m, multiplet. ¹³C NMR spectra were reported in ppm, referenced to CDCl₃ or DMSO-*d*₆. Melting points (m.p.) of compounds were determined on a Barnstead Electrothermal 9100 instrument (Essex, UK) and uncorrected. Measurements by high-resolution mass spectrometry (HRMS) were performed by a JMS-700 with an electron ionization (EI) or fast atom bombardment (FAB) source (JEOL, Japan) or a Xevo G2-XS QToF with an ESI source [Waters, Milford, MA, USA; KAIST Analysis Center for Research Advancement (KARA), Daejeon, Republic of Korea]. Synthetic A β ₄₀ (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVV) and A β ₄₂ (DAEFRHDSGYEVHHQKLVFFAEDVGSNKGAIIGLMVGGVVIA) were obtained from Peptide Institute (Osaka, Japan) and purified by high-performance liquid chromatography using Intakt Cadenza CD-C18 (Intakt, Portland, OR, USA), Zorbax 300SB-C18 (Agilent), or Xbridge peptide BEH-C18 (Waters) columns. Electronic absorption (Abs) spectra were recorded on an Agilent 8453 UV–visible spectrophotometer (Agilent, Santa Clara, CA, USA). HEPES [2-(4-(2-hydroxyethyl)piperazin-1-yl)ethanesulfonic acid] and ammonium acetate were purchased from Sigma-Aldrich. The buffered solution was prepared in doubly distilled water [ddH₂O; Milli-Q Direct 16 system (18.2 M Ω ·cm; Merck KGaA, Darmstadt, Germany)]. Trace metal contamination was removed from all solutions used for experiments by treating with Chelex (Sigma-Aldrich) overnight. The samples were prepared using Eppendorf tubes (Eppendorf, Hamburg, Germany) unless otherwise stated. Images gained by gel/Western blot were visualized by a ChemiDoc MP imaging system (Bio-Rad,

Hercules, CA, USA). Morphologies of peptide aggregates produced from the aggregation experiments were taken on a Tecnai F20 transmission electron microscope (FEI Company, Eindhoven, Netherlands; KARA). ESI-MS and tandem MS (MS²) experiments were performed by a Xevo G2-XS QToF mass spectrometer with an ESI source (Waters). The human neuroblastoma SH-SY5Y (5Y) cell line was purchased from the American Type Culture Collection (Manassas, VA, USA). A microplate reader (SpectraMax M5; Molecular Devices, Sunnyvale, CA, USA) was used to measure the absorbance for the MTT assay [MTT = 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; Biosesang, Seoul, Republic of Korea].

Synthesis of 2a.

1b (7-Methoxy-1,2-dihydro-3H-indazol-3-one). **1b** was synthesized following procedures described in the patent literature.¹ 2-Amino-3-methoxybenzoic acid (2.5 g, 15.0 mmol) was dissolved in HCl (8.4 M, aq, 30 mL) at 0 °C and stirred for 5 min. Sodium nitrite (NaNO₂; 1.0 g, 15.0 mmol) was dissolved in H₂O (10 mL) and then slowly added dropwise to the solution at 0 °C for 30 min. SnCl₂·2H₂O (16.9 g, 74.8 mmol) was dissolved in HCl (11.3 M, aq, 20 mL) and, subsequently, added dropwise to the mixture at 0 °C. After 30 min, the solution was warmed to room temperature and stirred for 24 h. The precipitated product was filtered, washed with HCl (3.0 M, aq) and CH₂Cl₂, and dried under the vacuum. The mixture was dissolved in HCl (1.0 M, aq, 100 mL) at room temperature and heated and stirred at 100 °C for 24 h. After completion of the reaction, the mixture was cooled at room temperature and neutralized with the saturated aqueous solution of sodium carbonate (100 mL) at 0 °C. The precipitated product was filtered, washed with H₂O, and dried in a vacuum oven. The crude product was recrystallized in ethanol to yield **1b** [*R*_f = 0.30 [hexanes:ethyl acetate (EtOAc) = 1:2]; white solid; 2.1 g, 12.9 mmol (yield = 86%); m.p.: 196–197 °C]. ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 11.50 (s, 1H), 10.42 (s, 1H), 7.12 (d, *J* = 8.0 Hz, 1H), 6.84 (t, *J* = 7.8 Hz, 1H), 6.75 (d, *J* = 7.6 Hz, 1H), 3.86 (s, 3H). ¹³C NMR [100 MHz, DMSO-*d*₆, δ (ppm)]: 156.52, 145.53, 134.28, 119.82, 114.34, 112.48, 106.50, 55.75. HRMS (*m/z*): [M + H]⁺ Calcd. for C₈H₉N₂O₂: 165.0659, found: 165.0658.

1c (1-Benzyl-7-methoxy-1,2-dihydro-3H-indazol-3-one). **1b** (1.9 g, 11.9 mmol) and sodium hydroxide (0.47 g, 11.9 mmol) were dissolved in H₂O (12 mL) at room temperature. Benzyl chloride (1.4 mL, 11.9 mmol) was then added and heated at 70 °C for 3 h. Upon completion of the reaction, the mixture was cooled at room temperature, and H₂O was added to precipitate the product. The precipitated product was filtered, washed with H₂O, and dried in a vacuum oven. The crude product was purified by recrystallization in benzene/*n*-heptane to obtain **1c** [*R*_f = 0.75 (hexanes:EtOAc = 1:1); ivory solid; 2.1 g, 8.3 mmol (yield = 70%); m.p.: 257–259 °C]. ¹H NMR

[400 MHz, DMSO-*d*₆, δ (ppm)]: 10.62 (s, 1H), 7.16–7.23 (m, 3H), 7.09–7.13 (m, 3H), 6.88 (t, *J* = 8.0 Hz, 1H), 6.80 (d, *J* = 8.0 Hz, 1H), 5.43 (s, 2H), 3.86 (s, 3H). ¹³C NMR [100 MHz, DMSO-*d*₆, δ (ppm)]: 155.35, 145.99, 139.40, 132.86, 128.83, 127.78, 127.67, 120.34, 115.50, 112.62, 107.47, 56.12, 54.10. HRMS (*m/z*): [M]⁺ Calcd. for C₁₅H₁₄N₂O₂: 254.1055, found: 254.1051.

1d [1-Benzyl-7-methoxy-2-(*p*-tolyl)-1,2-dihydro-3*H*-indazol-3-one]. **1c** (1.1 g, 4.3 mmol), *p*-tolylboronic acid (1.8 g, 13.0 mmol), and Cu(OAc)₂ (0.8 g, 4.3 mmol) were dissolved in CH₂Cl₂ (8.6 mL) and pyridine (7.3 mL) at room temperature and stirred for 24 h. The reaction was quenched with HCl (1.0 M, aq), and the mixture was extracted with EtOAc (three times, 100 mL). The organic layer was separated, washed with brine, and dried over anhydrous sodium sulfate (Na₂SO₄). After filtration, the mixture was concentrated under reduced pressure, and the crude product was purified by column chromatography (SiO₂; hexanes:EtOAc = from 9:1 to 4:1) to obtain **1d** [*R*_f = 0.40 (hexanes:EtOAc = 2:1); white solid; 1.3 g, 3.8 mmol (yield = 84%); m.p.: 143–144 °C]. ¹H NMR [300 MHz, DMSO-*d*₆, δ (ppm)]: 7.48 (d, *J* = 8.4 Hz, 2H), 7.40 (d, *J* = 8.4 Hz, 2H), 7.29 (d, *J* = 7.3 Hz, 1H), 7.20 (d, *J* = 7.7 Hz, 1H), 7.08–7.17 (m, 4H), 6.71 (d, *J* = 7.9 Hz, 2H), 4.86 (s, 2H), 4.09 (s, 3H), 2.39 (s, 3H). ¹³C NMR [100 MHz, CDCl₃, δ (ppm)]: 162.43, 147.11, 138.77, 136.06, 133.03, 132.52, 129.78, 129.00, 128.00, 127.93, 124.09, 123.75, 122.43, 116.19, 112.65, 55.73, 52.85, 21.11. HRMS (*m/z*): [M]⁺ Calcd. for C₂₂H₂₀N₂O₂: 344.1525, found: 344.1525.

1e [1-Benzyl-7-hydroxy-2-(*p*-tolyl)-1,2-dihydro-3*H*-indazol-3-one]. **1d** (1.0 g, 2.9 mmol) was dissolved in CH₂Cl₂ (25 mL). Boron tribromide (BBr₃; 1.0 M in CH₂Cl₂, 5.8 mL, 5.8 mmol) was gradually added at 0 °C for 1 h. The reaction was quenched with HCl (1.0 M, aq), and the mixture was extracted with EtOAc (three times, 150 mL). The organic layer was separated, washed with brine, and dried over anhydrous Na₂SO₄. After filtration, the crude product was recrystallized in hexanes/EtOAc to obtain **1e** [*R*_f = 0.25 (hexanes:EtOAc = 2:1); white solid; 0.9 g, 2.8 mmol (yield = 98%); m.p.: 224–225 °C]. ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 10.78 (s, 1H), 7.44 (d, *J* = 8.8 Hz, 2H), 7.36 (d, *J* = 8.8 Hz, 2H), 7.00–7.10 (m, 6H), 6.73 (d, *J* = 8.0 Hz, 2H), 4.86 (s, 2H), 2.35 (s, 3H). ¹³C NMR [100 MHz, DMSO-*d*₆, δ (ppm)]: 162.24, 145.67, 138.31, 135.97, 133.32, 132.91, 130.30, 129.46, 128.51, 128.46, 125.12, 123.68, 122.16, 118.23, 114.18, 52.19, 21.17. HRMS (*m/z*): [M]⁺ Calcd. for C₂₂H₂₀N₂O₂: 330.1368, found: 330.1367.

2a [1-Benzyl-2-(*p*-tolyl)-1*H*-indazole-3,4,7(2*H*)-trione]. **1e** (0.1 g, 0.3 mmol) was dissolved in acetonitrile (CH₃CN; 3.0 mL) and tetrahydrofuran (THF; 3.0 mL). Ceric ammonium nitrate (CAN) was dissolved in H₂O (3.0 mL) and then slowly added dropwise to the mixture at 0 °C. The mixture was warmed to room temperature and stirred for 1 h. The reaction was quenched with H₂O, and the mixture was then extracted with EtOAc (three times, 50 mL). The

organic layer was separated, washed with brine, and dried over anhydrous Na₂SO₄. After filtration, the mixture was concentrated under reduced pressure, and the crude product was purified by column chromatography (SiO₂; hexanes:EtOAc = from 2:1 to 1:9) to obtain **2a** [*R*_f = 0.20 (hexanes:EtOAc = 2:1); red-orange solid; 75 mg, 0.2 mmol (yield = 72%); m.p.: 180–181 °C]. ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 7.21–7.30 (m, 5 H), 7.08 (d, *J* = 8 Hz, 2H), 6.82–6.92 (m, 4H), 5.46 (s, 2H), 2.35 (s, 3H). ¹³C NMR [100 MHz, DMSO-*d*₆, δ (ppm)]: 179.15, 178.96, 157.53, 140.37, 139.97, 139.84, 135.65, 133.91, 129.95, 128.69, 128.63, 128.40, 128.11, 126.70, 103.75, 50.35, 20.82. HRMS (*m/z*): [M]⁺ Calcd. for C₂₁H₁₆N₂O₃: 344.1161, found: 344.1162.

Synthesis of 1 [2-(*p*-Tolyl)-1*H*-indazole-3,4,7(2*H*)-trione]. **2a** (0.2 g, 0.5 mmol) and palladium hydroxide on carbon [Pd(OH)₂/C; 0.033 g, 0.046 mmol] were dissolved in CH₃OH (18 mL). The mixture was stirred at room temperature for 2 h under H₂ gas. After completion of the reaction, the mixture was filtered through Celite and washed with EtOAc (200 mL). The filtrate was concentrated under reduced pressure, and the crude product was purified by column chromatography (SiO₂; CH₃OH:EtOAc = 1:9) to obtain **1** [*R*_f = 0.35 (CH₃OH:EtOAc = 1:9); red-violet solid; 112 mg, 0.4 mmol (yield = 95%); m.p.: decomposed over 300 °C]. ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 7.89 (d, *J* = 8.0 Hz, 2H), 7.19 (d, *J* = 8.0 Hz, 2H), 6.49–6.61 (m, 2H), 6.46 (d, *J* = 10.3 Hz, 1H), 2.30 (s, 3H). ¹³C NMR [100 MHz, DMSO-*d*₆, δ (ppm)]: 181.22, 176.53, 161.62, 143.88, 142.97, 137.52, 136.19, 133.59, 129.01, 119.26, 20.56. HRMS (*m/z*): [M]⁺ Calcd. for C₁₄H₁₀N₂O₃: 254.0691, found: 254.0692.

Preparation of A β . A β was dissolved in ammonium hydroxide [NH₄OH; 1% w/w, aq; Sigma-Aldrich). The solutions were aliquoted, lyophilized overnight, and stored at –80 °C. A stock solution of A β was prepared by dissolving the lyophilized peptide with NH₄OH (1% w/w, aq; 10 μ L) followed by addition of ddH₂O. The concentration of the solution containing A β was determined by measuring the absorbance at 280 nm (ϵ = 1,450 M^{–1}cm^{–1} for A β ₄₀; ϵ = 1,490 M^{–1}cm^{–1} for A β ₄₂).²

A β Aggregation Experiments. A β samples were prepared in the buffered solution (20 mM HEPES, pH 6.8 or pH 7.4, 150 mM NaCl) following previously reported procedures.^{2,3} For the inhibition studies, compounds (final concentration, 25 μ M; 1% v/v DMSO) were added to the samples of A β (25 μ M) in the absence and presence of CuCl₂ or ZnCl₂ (25 μ M) followed by incubation for 24 h at 37 °C with constant agitation. For the disaggregation studies, A β (25 μ M)

was incubated with and without CuCl₂ or ZnCl₂ (25 μM) for 24 h at 37 °C with constant agitation to produce preformed Aβ aggregates. The resultant Aβ aggregates were then treated with compounds (25 μM; 1% v/v DMSO) and incubated for an additional 24 h with constant agitation. For the experiments under anaerobic conditions, all samples were prepared following the procedure described above for the aerobic samples under quiescent conditions in a N₂ (g)-filled glove box.

Gel/Western Blot. The resultant Aβ species from the inhibition and disaggregation experiments were analyzed by gel/Western blot using an anti-Aβ antibody (6E10; Covance, Princeton, NJ, USA).^{2,3} Each sample (10 μL) was separated on a 10–20% tricine gel (Invitrogen). Following separation, the peptides were transferred onto nitrocellulose membranes and blocked with bovine serum albumin (BSA; 3% w/v; Sigma-Aldrich) in Tris-buffered saline (TBS) containing 0.1% v/v Tween-20 (Sigma-Aldrich) (TBS-T) overnight at 4 °C. The membranes were incubated with 6E10 (1:2,000) in the solution of BSA (2% w/v in TBS-T) for 4 h at room temperature. After washing with TBS-T (three times, 10 min), a horseradish peroxidase-conjugated goat anti-mouse secondary antibody (1:5,000 in 2% w/v BSA in TBS-T; Cayman Chemical Company, Ann Arbor, MI, USA) was added for 1 h at room temperature. A homemade ECL kit⁴ was used to visualize gel/Western blots on a ChemiDoc MP Imaging System (Bio-Rad).

TEM. Samples for TEM were prepared according to the procedures described in Aβ aggregation experiments. Glow-discharged grids (Formvar/Carbon 300-mesh; Electron Microscopy Sciences, Hatfield, PA, USA) were treated with the samples (5 μL) for 2 min at room temperature. Excess samples were removed using filter paper followed by washing with ddH₂O three times. Each grid incubated with uranyl acetate (1% w/v, aq; 5 μL; Polysciences, Warrington, PA, USA) for 2 min was blotted off and dried overnight at room temperature. Images for each sample were taken on a transmission electron microscope (200 kV; 29,000x magnification). The location of the samples on the grids was randomly picked, taking more than 20 images from each grid.

ESI-MS. Compounds (25 μM; 1% v/v DMSO) were incubated with and without Aβ₄₂ (25 μM) in the absence and presence of CuCl₂ or ZnCl₂ (25 μM) in 20 mM ammonium acetate, pH 6.8 or pH 7.4 for 6 h or 24 h at 37 °C with constant agitation. The samples were diluted 25-fold with LC-grade H₂O and then injected into the mass spectrometer unless otherwise stated. The capillary voltage, sampling cone voltage, source temperature, desolvation temperature, cone gas flow, and

desolvation gas flow were set to 2.5 kV, 40 V, 150 °C, 250 °C, 30 L/h, and 500 L/h, respectively.

ESI-MS². The covalent cross-link between metal-free monomeric A β ₄₂ and **2a** as well as singly oxidized A β ₄₂ species generated with **1**, **2a**, and **3** in the presence of Cu(II) were further analyzed by ESI-MS². Mass spectra for the samples prepared under metal-free conditions were obtained without dilution with LC-grade H₂O before injection into the mass spectrometer. The ESI parameters and experimental conditions were the same as those used for the ESI-MS experiments. Collision-induced dissociation was performed by applying the collision energy at 58–65 eV.

Docking Studies. MM2 energy minimization in Chem3D 21.0.0 was used to optimize the structure of **2a** and **2b**. The structures of A β ₄₂ monomer (xx98156⁵) with **2a** and **2b** were prepared using AutoDock Tools,⁶ imported into PyRx,⁷ and used to run AutoDock Vina 1.5.7 software.⁸ The exhaustiveness for the docking runs was set at 1,024. Docked models of compounds with the peptide were visualized using Pymol 2.5.4.

Chemical Transformation of 2a. **2a** (25 μ M; 1% v/v DMSO) was incubated for 24 h at 37 °C in 20 mM HEPES, pH 7.4, 150 mM NaCl (for Abs spectroscopy) or 20 mM ammonium acetate, pH 7.4 (for ESI-MS). For the analysis of its chemical transformation, spectral changes were monitored by Abs spectroscopy and ESI-MS. For comparison with spectral features of **2b**, the Abs spectrum of **2b** (25 μ M; 1% v/v DMSO) was obtained in 20 mM HEPES, pH 7.4, 150 mM NaCl. The isotope patterns of the peaks corresponding to **2a** and its transformed species shown in the mass spectra were simulated according to their chemical formula using enviPat Web.⁹

Synthesis of 2b.

2b-i [1-Benzyl-6-bromo-4,7-dihydroxy-2-(*p*-tolyl)-1,2-dihydro-3*H*-indazol-3-one] and **2b-ii [1-benzyl-6-bromo-2-(*p*-tolyl)-1*H*-indazole-3,4,7(2*H*)-trione]**. **1e** (0.2 g, 0.6 mmol) was dissolved in CH₂Cl₂ (6.0 mL). Br₂ (0.034 mL, 0.7 mmol) was dissolved in CH₂Cl₂ (0.6 mL) and then slowly added dropwise to the solution at 0 °C. The mixture was warmed to room temperature and stirred for 15 min. This process was repeated with an additional Br₂ (0.034 mL, 0.7 mmol) dissolved in CH₂Cl₂ (6.0 mL). The reaction was quenched with H₂O, and the mixture was extracted with EtOAc (three times, 50 mL). The organic layer was separated, washed with brine, and dried over anhydrous Na₂SO₄. After filtration, the mixture was concentrated under reduced pressure,

and the crude product was purified by column chromatography (SiO₂; hexanes:EtOAc = from 4:1 to 1:4) to yield **2b-i** [*R*_f = 0.70 (hexanes:EtOAc = 1:1); pale pink solid; 116 mg, 0.3 mmol (yield = 45%); m.p.: 174–175 °C] and **2b-ii** [*R*_f = 0.10 (hexanes:EtOAc = 1:1); purple solid; 107 mg, 0.3 mmol (yield = 42%); m.p.: 178–179 °C]. For **2b-i**, ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 9.85 (s, 1H), 9.57 (s, 1H), 7.37–7.39 (m, 4H), 7.12–7.15 (m, 4H), 6.74 (d, *J* = 7.2 Hz, 2H), 6.61 (s, 1H), 4.83 (s, 2H), 2.35 (s, 3H). ¹³C NMR [100 MHz, CDCl₃, δ (ppm)]: 162.87, 149.02, 137.06, 136.31, 132.80, 132.70, 131.62, 130.16, 129.12, 128.48, 128.36, 123.76, 115.11, 111.17, 108.55, 52.69, 21.23. HRMS (*m/z*): [*M*]⁺ Calcd. for C₂₁H₁₆N₂O₃: 424.0423, found: 424.0420. For **2b-ii**, ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 7.42 (s, 1H), 7.19–7.25 (m, 5H), 6.99 (d, *J* = 8.4 Hz, 2H), 6.88 (d, *J* = 7.6 Hz, 2H), 5.44 (s, 2H), 2.31 (s, 3H). ¹³C NMR [100 MHz, CDCl₃, δ (ppm)]: 176.26, 172.34, 157.89, 141.94, 140.83, 139.36, 134.22, 133.32, 130.61, 129.12, 129.07, 128.66, 127.89, 127.09, 106.62, 51.61, 21.43. HRMS (*m/z*): [*M*]⁺ Calcd. for C₂₁H₁₆N₂O₃: 422.0266, found: 422.0267.

Conversion of 2b-i to 2b-ii. **2b-i** (0.4 g, 0.9 mmol) was dissolved in a mixture of CH₃CN (8.0 mL) and THF (8.0 mL). CAN (1.2 g, 2.1 mmol) was dissolved in H₂O (8.0 mL) and then added dropwise to the solution at 0 °C. The mixture was subsequently warmed to room temperature and stirred for 30 min. The reaction was quenched with H₂O, and the mixture was extracted with EtOAc (three times, 100 mL). The organic layer was separated, washed with brine, and dried over anhydrous Na₂SO₄. Following filtration, the mixture was concentrated under reduced pressure. The crude product was purified by column chromatography (SiO₂; hexanes:EtOAc = from 1:1 to 1:4) to yield **2b-ii** (78 mg, yield = 98%).

2b-iii [1-Benzyl-6-methoxy-2-(*p*-tolyl)-1*H*-indazole-3,4,7(2*H*)-trione]. **2b-ii** (0.1 g, 0.2 mmol) was dissolved in CH₃OH (4.7 mL). The solution of sodium methoxide (4.4 M in CH₃OH, 0.2 mL, 0.8 mmol) was added dropwise to the solution of **2b-ii** at 0 °C. The mixture was then warmed to room temperature and stirred for 1 h. The reaction was quenched with HCl (1.0 M, aq), and the mixture was extracted with EtOAc (three times, 50 mL). The organic layer was separated, washed with brine, and dried over anhydrous Na₂SO₄. After filtration, the mixture was concentrated under reduced pressure. The crude product was purified by column chromatography (SiO₂; hexanes:EtOAc = from 2:1 to 1:1) to obtain **2b-iii** [*R*_f = 0.45 (hexanes:EtOAc = 1:2); red solid; 34 mg, 0.091 mmol (yield = 49%); m.p.: 227–228 °C]. ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 7.25 (d, *J* = 8.0 Hz, 2H), 7.20–7.22 (m, 4H), 7.02 (d, *J* = 8.0 Hz, 2H), 6.85 (d, *J* = 7.6 Hz, 2H), 5.46 (s, 2H), 4.24 (s, 3H), 2.32 (s, 3H). ¹³C NMR [100 MHz, CDCl₃, δ (ppm)]: 172.45, 172.15, 160.31, 140.81, 139.77, 133.36, 130.57, 129.04, 128.98, 128.68, 128.10, 127.23, 115.17, 104.18, 63.07, 51.43, 21.43. HRMS (*m/z*): [*M*]⁺ Calcd. for C₂₁H₁₆N₂O₃: 374.1267, found: 374.1268.

2b [1-Benzyl-6-hydroxy-2-(*p*-tolyl)-1*H*-indazole-3,4,7(2*H*)-trione]. **2b-iii** (0.03 g, 0.1 mmol) was dissolved in CH₂Cl₂ (2.4 mL). BBr₃ (1.0 M in CH₂Cl₂, 0.1 mL, 0.1 mmol) was then added to the solution at 0 °C for 1 h. The reaction was quenched with HCl (1.0 M, aq), and the mixture was extracted with EtOAc (three times, 50 mL). The organic layer was separated, washed with brine, and dried over anhydrous Na₂SO₄. Following filtration, the mixture was concentrated under reduced pressure. The crude product was purified by column chromatography (SiO₂; CH₃OH:EtOAc = from 1:9 to 1:3) to obtain **2b** [*R*_f = 0.15 (CH₃OH:EtOAc = 1:9); gray solid; 24 mg, 0.067 mmol (yield = 83%); m.p.: decomposed over 300 °C]. ¹H NMR [400 MHz, DMSO-*d*₆, δ (ppm)]: 7.24–7.28 (m, 6 H), 7.05 (d, *J* = 8.0 Hz, 2H), 6.82–6.84 (m, 2H), 5.71 (s, 2H), 2.30 (s, 3H), 2.35 (s, 3H). ¹³C NMR [100 MHz, DMSO-*d*₆, δ (ppm)]: 175.13, 171.06, 165.09, 159.10, 146.54, 139.06, 134.95, 129.83, 129.63, 128.62, 128.15, 127.92, 126.70, 103.50, 101.01, 49.70, 20.80. HRMS (*m/z*): [M + Br][−] Calcd. for C₂₁H₁₆N₂O₄: 439.0293, found: 439.0142.

Solution Speciation Studies. The acidity constant (*K*_a) of **2b** was determined through Abs variable-pH titration spectroscopy.² The solution of **2b** (50 μ M; 1% v/v DMSO; 10 mM NaOH, pH 12, 100 mM NaCl) was titrated with small aliquots of HCl to obtain at least 30 spectra in the pH range from 0.3 to 12. Using the measured p*K*_a values, the metal-binding properties of the compound were analyzed through Abs variable-pH titration spectroscopy. Small aliquots of HCl were added into the solution of **2a** (50 μ M; 1% v/v DMSO) with CuCl₂ or ZnCl₂ (25 μ M). At least 30 spectra were acquired in the range of pH 0.9–7.8. The values of p*K*_a and stability constants were calculated by the HypSpec program (Protonic Software, Leeds, UK).¹⁰ Solution speciation diagrams were modeled in the Hyss2009 program (Protonic Software).¹¹

Metal-binding Studies. The binding stoichiometry and affinity of **1** for Cu(II) were determined by Job's method of continuous variation¹² and Cu(II)-titration experiments, respectively, employing Abs spectroscopy. A mixture of **1** (0.63, 1.88, 5, 7.5, 10, 11.25, 13.75, 15, 16.25, 18.75, 20, 21.25, 22.5, 23.13, 23.75, 24.38, and 25 μ M; 1% v/v DMSO) and CuCl₂ (0.63, 1.88, 5, 7.5, 10, 11.25, 13.75, 15, 16.25, 18.75, 20, 21.25, 22.5, 23.13, 23.75, 24.38, and 25 μ M) was prepared in H₂O with a fixed total concentration (25 μ M). The changes in Abs at 250 nm were plotted as a function of the mole fraction of Cu(II) to obtain a Job plot. To estimate the Cu(II)-binding affinity of **1**, the Abs values of **1** (25 μ M; 1% v/v DMSO) upon titration with various concentrations of CuCl₂ (0.75, 1, 1.5, 1.75, 5, 12.5, 17.5, 30, and 45 μ M) in H₂O were measured. The alteration in Abs at 250 nm upon increasing the concentration of Cu(II) was plotted and fitted using the online software

BindFit.¹³ The 1:2 Cu(II)-to-ligand (L) system constructed based on equations 1 and 2 was chosen in the program.^{14,15} Note that $\varepsilon_{\Delta\text{Cu(L)}}$ and $\varepsilon_{\Delta\text{Cu(L)}_2}$ represent the change in the molar absorption coefficients of Cu(L) and Cu(L)₂ complexes, respectively, and [Cu(II)]₀ indicates the total concentration of Cu(II).

$$\Delta\text{Abs}_{280\text{ nm}} = \frac{\varepsilon_{\Delta\text{Cu(L)}}[\text{Cu(II)}]_0 K_{a1}[\text{L}] + 2\varepsilon_{\Delta\text{Cu(L)}_2}[\text{Cu(II)}]_0 K_{a1}K_{a2}[\text{L}]^2}{1 + K_{a1}[\text{L}] + K_{a1}K_{a2}[\text{L}]^2} \quad (\text{equation 1})$$

$$K_d = \frac{1}{K_a} \quad (\text{equation 2})$$

In addition, to investigate the Zn(II)- and Cu(II)-binding properties of **1** and **6**, respectively, the changes in Abs of **1** (25 μM ; 1% v/v DMSO; 20 mM HEPES, pH 7.4, 150 mM NaCl) and **6** (25 μM ; 1% v/v DMSO; H₂O) upon treatment of ZnCl₂ (25 μM) or CuCl₂ (25 μM) were monitored.

Cell Culture. 5Y cell line was maintained in media containing minimum essential medium (MEM; 50% v/v; GIBCO, Grand Island, NY, USA) and F-12 (50% v/v; GIBCO) supplemented with fetal bovine serum (FBS, 10% v/v; Sigma-Aldrich) and penicillin (100 U/mL) with streptomycin (100 mg/mL; GIBCO). The cells were grown and maintained at 37 °C in a humidified atmosphere with 5% CO₂. The cells used for our studies did not indicate mycoplasma contamination.

Cell Viability Studies. Cell viability was determined by the MTT assay. Compounds (125 μM ; 1% v/v DMSO) with and without A β (125 μM) were preincubated in the absence and presence of CuCl₂ or ZnCl₂ (125 μM) for 24 h at 37 °C with constant agitation in 20 mM HEPES, pH 6.8 or pH 7.4, 150 mM NaCl. Cells were seeded in a 96-well plate (20,000 cells/100 μL ; SPL Life Sciences, Pocheon, Gyeonggi-do, Republic of Korea) and treated with the samples (final concentrations, 25 μM for compounds, A β , and metal ions). After 24 h of incubation, the cells were washed once with PBS (pH 7.4). MTT [5 mg/mL in PBS (pH 7.4); 25 μL] was added to each well, and the plate was incubated for 4 h at 37 °C. Formazan produced by cells was solubilized using an acidic solution of *N,N*-dimethylformamide (pH 4.5, 50% v/v, aq; Daejung Chemicals, Busan, Republic of Korea) and sodium dodecyl sulfate (20% w/v; Wako Chemicals, Richmond, VA, USA) overnight at room temperature in the dark. The absorbance was measured at 600 nm by a microplate reader (Molecular Devices). Cell viability was calculated, compared to that of the cells treated with an equivalent amount of the buffered solution. Data are presented as mean $\pm$ s.e.m. for $n = 6$ examined over three independent experiments. For the statistical analysis, a two-sided unpaired

Student's *t*-test was used. Statistical difference was considered significant at $*P < 0.05$, $**P < 0.01$, or $***P < 0.001$.




Fig. S1 ¹H (400 MHz, top) and ¹³C (100 MHz, bottom) NMR spectra of **1** in DMSO-*d*₆.




Fig. S2 ¹H (400 MHz, top) and ¹³C (100 MHz, bottom) NMR spectra of **2a** in DMSO-*d*₆.




Fig. S3 ¹H (400 MHz, top) and ¹³C (100 MHz, bottom) NMR spectra of **3** in DMSO-*d*₆.




Fig. S4 ^1H (400 MHz, top) and ^{13}C (100 MHz, bottom) NMR spectra of **4** in $\text{DMSO}-d_6$.




Fig. S5 ^1H (400 MHz, top left), ^1H (shaking with D_2O , 400 MHz, top right), and ^{13}C (100 MHz, bottom) NMR spectra of **5** in $\text{DMSO-}d_6$.




Fig. S6 Original gel images from Fig. 2, 5, 6, and S13.




Fig. S7 Proposed reaction pathways between **2a** and A β . (a) Proposed chemical transformation of **2a** into **2b**. In aqueous media, the **BQ** moiety in **2a** can be transformed into **BQ(H₂O)** in **2a-I**, which then rearranges into **THB** in **2a-II**. This intermediate undergoes auto-oxidation, leading to the formation of **2-hydroxy-BQ** in **2b**. The oxidation of **2a-I** by **2a** can also generate **2b**. (b) Proposed covalent and non-covalent adduct formation of **2a** and its chemically converted forms with A β , respectively. Our ESI-MS studies indicate that **BQ** in **2a** forms covalent adducts with Lys residues in A β , whereas **2b** produces non-covalent adducts with A β . (c) Possible interactions of **2a** and **2b** with metal-free A β_{42} (xx98156⁵), as visualized through docking studies. Nine docked models of **2a** and **2b** were obtained with binding energies ranging from -5.9 to -5.5 kcal/mol.




Fig. S8 Chemical transformation of **2a** monitored by ESI-MS. (a) Mass spectra of **2a** upon incubation for 6 h and 24 h. Conditions: **[2a]** = 25 μ M (1% v/v DMSO); 20 mM ammonium acetate; 37 $^{\circ}$ C; 24 h; constant agitation. The samples were diluted 25-fold with H_2O before injection into the mass spectrometer. (b) Simulated mass spectra of **2a** and its transformed species.




Fig. S9 Characterization of **2b**. (a) ^1H (400 MHz, top) and ^{13}C (100 MHz, bottom) NMR spectra of **2b** in $\text{DMSO-}d_6$. (b) Abs spectra of **2b** and **2a**. Conditions: [compound] = 25 μM (1% v/v DMSO); 20 mM HEPES, pH 7.4, 150 mM NaCl; 37 $^\circ\text{C}$; 24 h; no agitation.




Fig. S10 Solution speciation studies of **2b** (L). The Abs variable-pH titration spectra (a), solution speciation diagram (F_L = fraction of species at given pH) (b), and pK_a values (c) of **2b** are depicted. The error in the last digit is shown in parentheses. Charges are omitted for clarity. Conditions: [**2b**] = 50 μ M; room temperature; I = 0.1 M NaCl.




Fig. S11 Abs spectra of **6** upon treatment of Cu(II). Conditions: [**6**] = 25 μ M (1% v/v DMSO); [Cu(II)] = 12.5, 25, and 125 μ M; H₂O; room temperature.




Fig. S12 Interaction of **2b** with Zn(II)–A β_{42} investigated by ESI–MS. Conditions: $[A\beta_{42}] = 25 \mu\text{M}$; $[Zn(II)] = 25 \mu\text{M}$; $[\mathbf{2b}] = 25 \mu\text{M}$ (1% v/v DMSO); 20 mM ammonium acetate, pH 7.4; 37 °C; 24 h; constant agitation. The samples were diluted 25-fold with H₂O before injection into the mass spectrometer.




Fig. S13 Influence of **2a** and **2b** on preformed Aβ aggregates generated in the absence and presence of metal ions. (a) Size distribution of the resultant Aβ species analyzed by gel/Western blot using 6E10. Lanes: (C) Aβ ± Cu(II) or Zn(II); (1) C + **2a**; (2) C + **2b**. The original gel images are shown in Fig. S6. (b) Morphologies of the resultant Aβ species investigated by TEM. Conditions: [Aβ] = 25 μM; [Cu(II) or Zn(II)] = 25 μM; [compound] = 25 μM (1% v/v DMSO); 20 mM HEPES, pH 7.4 [for metal-free and Zn(II)-containing samples] or pH 6.8 [for Cu(II)-containing samples], 150 mM NaCl; 37 °C; 24 h; constant agitation. Scale bar = 200 nm.




Fig. S14 Cu(II)-S1 binding properties of **1** determined by Abs spectroscopy. (a) Job plot of **1** with Cu(II). Conditions: [**1**] = 0.63–25 μM (1% v/v DMSO); [Cu(II)] = 0.63–25 μM ; H₂O; room temperature. (b) Abs spectra of **1** upon treatment of Cu(II). Conditions: [**1**] = 25 μM (1% v/v DMSO); [Cu(II)] = 0.75–45 μM ; H₂O; room temperature. (c) Change in Abs at 250 nm of **1** fitted as a function of [Cu(II)]. The data were fitted using the online software BindFit¹³ to estimate the K_d values for Cu(II) complexes of **1**. Data are presented as mean $\pm$ s.e.m. for $n = 3$.




Fig. S15 Abs spectra of **1** upon treatment of Zn(II). Conditions: [**1**] = 25 μ M (1% v/v DMSO); [Zn(II)] = 25 μ M; 20 mM HEPES, pH 7.4, 150 mM NaCl; room temperature.




Fig. S16 Interaction of compounds with $A\beta_{42}$ in the presence of $Zn(II)$ analyzed by ESI-MS. Conditions: $[A\beta_{42}] = 25 \mu M$; $[Zn(II)] = 25 \mu M$; [compound] = $25 \mu M$ (1% v/v DMSO); 20 mM ammonium acetate, pH 7.4; 37 °C; 24 h; constant agitation. The samples were diluted 25-fold with H_2O before injection into the mass spectrometer.




Fig. S17 ESI-MS² analysis of singly oxidized A β_{42} obtained by incubation with **3**. Conditions: [A β_{42}] = 25 μ M; [Cu(II)] = 25 μ M; [**3**] = 25 μ M (1% v/v DMSO); 20 mM ammonium acetate, pH 6.8; 37 °C; 24 h; constant agitation. The samples were diluted 25-fold with H₂O before injection into the mass spectrometer.

References

1. P. I. Eacho, P. S. Foxworthy-Mason, H.-S. Lin, J. E. Lopez, M. K. Mosior and M. E. Richett, World Intellectual Property Organization, WO2004093872 A1, 2004.
2. Y. Yi, Y. Lin, J. Han, H. J. Lee, N. Park, G. Nam, Y. S. Park, Y.-H. Lee and M. H. Lim, *Chem. Sci.*, 2021, **12**, 2456.
3. M. Kim, G. Gupta, J. Lee, C. Na, J. Kwak, Y. Lin, Y.-H. Lee, M. H. Lim and C. Y. Lee, *Inorg. Chem. Front.*, 2024, **11**, 1966.
4. D. D. Mruk and C. Y. Cheng, *Spermatogenesis*, 2011, **1**, 121.
5. W. Yang, B. S. Kim, Y. Lin, D. Ito, J. H. Kim, Y.-H. Lee and W. Yu, *bioRxiv*, 2021, preprint, DOI: 10.1101/2021.08.23.457317.
6. G. M. Morris, R. Huey, W. Lindstrom, M. F. Sanner, R. K. Belew, D. S. Goodsell and A. J. Olson, *J. Comput. Chem.*, 2009, **30**, 2785.
7. S. Dallakyan and A. J. Olson, in *Chemical Biology. Methods in Molecular Biology*, ed. J. E. Hempel, C. H. Williams, C. C. Hong, Humana Press, New York, 2015, vol. 1263, pp. 243–250.
8. O. Trott and A. J. Olson, *J. Comput. Chem.*, 2010, **31**, 455.
9. M. Loos, C. Gerber, F. Corona, J. Hollender and H. Singer, *Anal. Chem.*, 2015, **87**, 5738.
10. P. Gans, A. Sabatini and A. Vacca, *Ann. Chim.*, 1999, **89**, 45.
11. L. Alderighi, P. Gans, A. Lenco, D. Peters, A. Sabatini and A. Vacca, *Coord. Chem. Rev.*, 1999, **184**, 311.
12. D. C. Harris, *Quantitative Chemical Analysis*, W. H. Freeman and Company, 2010.
13. BindFit v0.5, <https://app.supramolecular.org/bindfit/>, (accessed June 2023).
14. P. Thordarson, *Chem. Soc. Rev.*, 2011, **40**, 1305.
15. D. B. Hibbert and P. Thordarson, *Chem. Commun.*, 2016, **52**, 12792.